natgillin/translations-raw huggingface dataset:
adrenaline, used for severe allergic reactions
adrenalin, ki se uporablja za hude alergijske reakcije
Adrenals
(mGy/MBq)
Adrenals
0,018
Adrenals
adrenalne žleze
adrenals
jenček
Adrenals
nadledvična žleza
Adrenals
Nadledvične žleze
Adrenals
Nadledvični žlezi
Adrenals3
nadledvična žleza3
ADROVANCE 70 mg/2,800 IU tablets ADROVANCE 70 mg/5,600 IU tablets Alendronic acid /colecalciferol
ADROVANCE 70 mg/2.800 i.e. tablete ADROVANCE 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
ADROVANCE 70 mg/2,800 IU tablets alendronic acid /colecalciferol
ADROVANCE 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
ADROVANCE 70 mg/2,800 IU tablets are available as modified capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710’ on the other.
ADROVANCE 70 mg/2.800 i.e. tablete imajo obliko modificirane kapsule, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘710’.
ADROVANCE 70 mg/2,800 IU tablets EU/1/06/364/001 – 2 tablets EU/1/06/364/002 – 4 tablets EU/1/06/364/003 – 6 tablets EU/1/06/364/004 – 12 tablets
ADROVANCE 70 mg/2.800 i.e. tablete EU/1/06/364/001 – 2 tableti EU/1/06/364/002 – 4 tablete EU/1/06/364/003 – 6 tablet EU/1/06/364/004 – 12 tablet
ADROVANCE 70 mg/5,600 IU tablets alendronic acid/colecalciferol
ADROVANCE 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
ADROVANCE 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270’ on the other.
ADROVANCE 70 mg/5.600 i.e. tablete imajo obliko modificiranega pravokotnika, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘270’.
ADROVANCE contains lactose and sucrose.
Zdravilo ADROVANCE vsebuje laktozo in saharozo
ADROVANCE should not be given to children and adolescents less than 18 years of age.
Zdravila ADROVANCE se ne sme dajati otrokom in mladostnikom, mlajšim od 18 let.
ADROVANCE should not be taken at bedtime or before arising for the day.
Bolnik zdravila ADROVANCE ne sme vzeti pred spanjem ali preden zjutraj vstane.
ADROVANCE should only be swallowed after getting up for the day with a full glass of water (not less than 200 ml).
Bolnik mora zdravilo ADROVANCE pogoltniti zjutraj, ko vstane, s polnim kozarcem vode (ne manj kot 200 ml).
ADROVANCE with food and drink
Zdravilo ADROVANCE skupaj s hrano in pijačo
ADRs (INTELENCE + BR versus Placebo + BR)
Neželeni učinki (zdravilo INTELENCE + BR v primerjavi s placebom + BR)
ADRs are listed by system organ class (SOC) and frequency: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000).
(≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in redki (≥ 1/10.000 do < 1/1.000).
ADRs considered by the investigator to be possibly, probably, or remotely related to the administration of capecitabine are listed in Table 4 for capecitabine given as monotherapy and in Table 5 for capecitabine given in combination with different chemotherapy regimens in multiple indications.
Neželeni učinki, ki so po mnenju raziskovalca morda, verjetno ali nejasno povezani z jemanjem kapecitabina, so navedeni v preglednici 4 za samostojno zdravljenje s kapecitabinom in v preglednici 5 za dajanje kapecitabina v kombinaciji z različnimi kemoterapijami pri več indikacijah.
ADRs from clinical studies (Table 1) are listed by MedDRA system organ class.
Neželeni učinki zdravila iz kliničnih študij (Preglednica 1) so navedeni po organskih sistemih klasifikacije MedDRA.
ADRs from psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies (Table 1) are listed by MedDRA system organ class.
Neželeni učinki zdravila iz kliničnih študij psoriaze, psoriatičnega artritisa in ankilozirajočega spondilitisa (preglednica 1) so navedeni po organskih sistemih klasifikacije MedDRA.
ADRs identified in post-marketing experience
Neželeni učinki, opaženi v okviru izkušenj v obdobju trženja
ADRs observed in clinical studies and reported from world-wide post-marketing use of golimumab are listed in Table 1.
DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
ADRs observed in clinical studies and reported from world-wide post-marketing use of golimumab are listed in Table 1.
Neželeni učinki, ki so jih opazili v kliničnih študijah in pri uporabi golimumaba v obdobju trženja po vsem svetu, so navedeni v Preglednici 1.
ADRs of moderate intensity or greater (≥ grade 2) reported in patients treated with INTELENCE are summarised in table 2 (background regimen is indicated as “BR”).
Neželeni učinki (ADR) zmerne jakosti ali hujši (≥ 2. stopnje), o katerih so poročali pri bolnikih, zdravljenih z zdravilom INTELENCE, so povzeti v preglednici 2 (osnovna shema zdravljenja je navedena kot “BR”).
ADRs related to afatinib.
Analgetiki
ADRs reported are on treatment or up to 28 days post treatment end date.
Do poročanih neželenih učinkov je prišlo v času zdravljenja ali v obdobju do 28 dni po zaključku zdravljenja.
ADRs reported from the use of Velphoro at doses from 250 mg iron/day to 3,000 mg iron/day in these patients (n=835) are listed in Table 1.
Neželeni učinki, o katerih so poročali pri uporabi zdravila Velphoro v odmerkih od 250 mg železa/dan do 3000 mg železa/dan pri teh bolnikih (n = 835), so navedeni v tabeli 1.
ADRs specific to residues from the manufacturing process
Neželeni učinki, specifični za ostanke postopka izdelave
ADRs which were reported are listed below by MedDRA body system organ class and by frequency.
Zabeleženi neželeni učinki so navedeni spodaj po organskih sistemih MedDRA in pogostnosti.
ADRs which were reported in melanoma patients are listed below by MedDRA body system organ class, frequency and grade of severity.
Neželeni učinki, o katerih so poročali pri bolnikih z melanomom, so navedeni spodaj po organskih sistemih MedDRA, pogostnosti in stopnji izrazitosti.
ADRs with an incidence of ≥10% were diarrhoea, nausea, vomiting, fatigue, liver laboratory test abnormalities, abdominal pain, decreased appetite, constipation, rash, blood creatinine increased, oesophageal disorder and anaemia.
Neželeni učinki s pogostnostjo ≥10 % so bili diareja, navzea, bruhanje, utrujenost, patološki laboratorijski izvidi jetrnih testov, bolečine v trebuhu, zmanjšan apetit, obstipacija, izpuščaj, zvišana vrednost kreatinina v krvi, s požiralnikom povezane motnje in anemija.
Adsorbed hepatitis B surface antigen produced in recombinant yeast cells 5.0 µg (Saccharomyces cerevisiae)
Adsorbiran površinski antigen hepatitisa B, pridobljen v rekombinantnih celicah kvasovk (Saccharomyces cerevisiae) 5,0 µg
Adsorbed hepatitis B surface antigen produced in recombinant yeast cells 5.0 µg (Saccharomyces cerevisiae)
Adsorbiran površinski antigen hepatitisa B, pridobljen v rekombinantnih celicah kvasovk 5,0 µg (Saccharomyces cerevisiae)
adsorbed on amorphous aluminium hydroxyphosphate sulphate (0.5 mg Al).
adsorbiran na amorfni aluminijev hidroksifosfat sulfat (0.5 mg Al).
Adsorption of active substance remaining in the stomach may be attempted by administration of active charcoal suspended in water.
Preostalo zdravilno učinkovino v želodcu skušajte adsorbirati z dajanjem aktivnega oglja, suspendiranega v vodi.
Adult
odrasel
Adult (73.7 kg)
Odrasli (73,7 kg)
Adult (>18 years)
Odrasli (>18 let)
Adult and adolescent (≥ 12 to < 18 years old and weighing ≥ 30 kg) patients who had a FEV1 percent predicted between 25% and 85% were enrolled.
Vključeni bolniki so bili odrasli in mladostniki (≥ 12 do < 18 let s telesno maso ≥ 30 kg, n = 28) s predvidenim odstotkom FEV1 med 25% in 85%.
Adult and adolescents (13 to 17 years of age) Reconstitution
Odrasli in mladostniki (stari od 13 do 17 let) Priprava koncentrata
Adult and elderly patients
Odrasli in starejši bolniki
Adult and older adults (≥65 years) population
Odrasli in starejši odrasli (≥ 65 let)
Adult and paediatric
odrasli in pediatrični bolniki
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma
Odrasli in pediatrični bolniki, stari 3 leta ali več, s ponavljajočim se ali napredujočim malignim gliomom
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma
Odrasli in pediatrični bolniki, stari 3 leta ali več, s ponavljajočim se ali napredujočim malignim gliomom:
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma
Odrasli in pediatrični bolniki, stari tri leta ali več, s ponavljajočim se ali napredujočim malignim gliomom
Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma:
Odrasli in pediatrični bolniki, stari tri leta ali več, s ponavljajočim se ali napredujočim malignim gliomom
Adult cancer patients with symptomatic anaemia receiving chemotherapy
Odrasli bolniki z rakom in simptomatično anemijo, ki se jih zdravi s kemoterapijo
Adult Child
Odrasla oseba Otrok
Adult chronic hepatitis C prior treatment non-responder patients
Kronični hepatitis C pri odraslih bolnikih, ki se na prejšnje zdravljenje niso odzvali
Adult Crohn’s disease
Crohnova bolezen pri odraslih
Adult Crohn’s disease
Crohnova bolezen pri odraslih bolnikih
Adult Crohn’s disease Flixabi is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolezen pri odraslih bolnikih Zdravilo Flixabi je indicirano za: zdravljenje zmerno do močno aktivne Crohnove bolezni pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus zdravljenja s kortikosteroidom in/ali zdravilom za zaviranje imunske odzivnosti, ali pri tistih, ki ne prenašajo tovrstne terapije ali ki imajo medicinske kontraindikacije zanjo, zdravljenje aktivne Crohnove bolezni s fistulami pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus konvencionalnega zdravljenja (vključno z antibiotiki, drenažo in imunosupresivno terapijo).
Adult Crohn’s disease Inflectra is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolezen pri odraslih bolnikih Zdravilo Inflectra je indicirano za: zdravljenje zmerno do močno aktivne Crohnove bolezni pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus zdravljenja s kortikosteroidom in/ali zdravilom za zaviranje imunske odzivnosti, ali pri tistih, ki ne prenašajo tovrstne terapije ali ki imajo medicinske kontraindikacije zanjo, zdravljenje aktivne Crohnove bolezni s fistulami pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus konvencionalnega zdravljenja (vključno z antibiotiki, drenažo in imunosupresivno terapijo).
Adult Crohn’s disease Remicade is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolezen pri odraslih bolnikih Remicade je indiciran za: zdravljenje zmerno do močno aktivne Crohnove bolezni pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus zdravljenja s kortikosteroidom in/ali zdravilom za zaviranje imunske odzivnosti, ali pri tistih, ki ne prenašajo tovrstne terapije ali ki imajo medicinske kontraindikacije zanjo, zdravljenje aktivne Crohnove bolezni s fistulami pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus konvencionalnega zdravljenja (vključno z antibiotiki, drenažo in imunosupresivno terapijo).
Adult Crohn’s disease Remsima is indicated for: treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. treatment of fistulising, active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).
Crohnova bolezen pri odraslih bolnikih Zdravilo Remsima je indicirano za: zdravljenje zmerno do močno aktivne Crohnove bolezni pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus zdravljenja s kortikosteroidom in/ali zdravilom za zaviranje imunske odzivnosti, ali pri tistih, ki ne prenašajo tovrstne terapije ali ki imajo medicinske kontraindikacije zanjo, zdravljenje aktivne Crohnove bolezni s fistulami pri odraslih bolnikih, ki se niso odzvali na celoten in ustrezen ciklus konvencionalnega zdravljenja (vključno z antibiotiki, drenažo in imunosupresivno terapijo).
Adult dose (D-Pan-H1N1-010)
Odmerek za odrasle5 (D-Pan-H1N1-010)
adult female
odrasla ženska
Adult females (including Elderly)
Odrasle ženske (vključno s starejšimi osebami)
Adult fleas are killed before they lay eggs for a minimum of 4 weeks after treatment.
Piriprol ubije odrasle bolhe, preden ležejo jajčeca, za najmanj 4 tedne po zdravljenju.
Adult haemodialysis patients
Odrasli bolniki, ki se zdravijo s hemodializo
Adult male
Odrasel moški
adult male (70 kg)
odrasel moški (70 kg)
Adult patients (16 years of age and above) should use Protopic 0.1% ointment.
Odrasli bolniki (stari 16 let in več) morajo uporabljati zdravilo Protopic 0,1 %.
Adult patients should use Protopic 0.1% ointment.
Odrasli bolniki morajo uporabljati zdravilo Protopic 0,1 % mazilo.
Adult patients suffering from acute coronary syndrome:
odraslih bolnikih z akutnim koronarnim sindromom:
Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
odraslih bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
odraslih bolnikih za preprečevanje aterotrombotičnih dogodkov z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Adult patients who have previously taken other antiviral medicines can take Kaletra tablets once daily as an 800 mg/200 mg dose if their doctor decides it is appropriate.
Odrasli bolniki, ki predhodno dobivali druga protiretrovirusna zdravila, lahko tablete zdravila Kaletra jemljejo enkrat na dan v odmerku 800 mg/200 mg, če njihov zdravnik presodi, da je to primerno.
Adult patients with a history of congestive heart failure, myocardial infarction and/or previous or current arrhythmic disorders must be closely monitored.
Odrasle bolnike s kongestivnim srčnim popuščanjem ali miokardnim infarktom v anamnezi oziroma s predhodnimi ali obstoječimi motnjami srčnega ritma morate strogo nadzorovati.
Adult patients with chronic renal failure Correction Phase
Odrasli bolniki s kronično odpovedjo ledvic Obdobje korekcije
Adult patients with creatinine clearance < 50 ml/min, including haemodialysis patients
Odrasli bolniki z očistkom kreatinina < 50 ml/min, vključno z bolniki na hemodializi
Adult patients with creatinine clearance < 50 ml/min, including haemodialysis patients:
Odrasli bolniki z očistkom kreatinina < 50 ml/min, vključno z bolniki na hemodializi
Adult patients with newly - diagnosed glioblastoma multiforme
Odrasli bolniki z novo diagnosticiranim multiformnim glioblastomom
Adult patients with newly-diagnosed glioblastoma multiforme
Odrasli bolniki z novo diagnosticiranim multiformnim glioblastomom:
Adult patients with newly-diagnosed glioblastoma multiforme:
Odrasli bolniki z novo diagnosticiranim multiformnim glioblastomom
Adult patients with RA
Odrasli bolniki z revmatoidnim artritisom
Adult patients with renal insufficiency not yet undergoing dialysis
Odrasli bolniki z zmanjšanim delovanjem ledvic, ki se še ne zdravijo z dializo
Adult patients with severe renal impairment (creatinine clearance of < 30 mL/minute) and patients with End Stage Renal Disease (ESRD) or on haemodialysis should be administered Ribavirin Mylan 200 mg/day.
Odrasli bolniki s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) in bolniki s končno odpovedjo ledvic (ESRD – end stage renal disease) ali tisti na hemodializi morajo prejemati 200 mg zdravila Ribavirin Mylan na dan.
Adult patients: Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA (see section 4.4).
Odrasli bolniki: Zdravilo Ribavirin BioPartners je indicirano v kombinaciji s interferonom alfa-2b za zdravljenje odraslih bolnikov kroničnega hepatitisa C katerekoli vrste razen genotipa 1, ki predhodno še niso bili zdravljeni, nimajo jetrne dekompenzacije, imajo zvišano vrednost alanin-aminotransferaze (ALT) in so pozitivni na ribonukleinsko kislino virusa hepatitisa C RNA–HCV (glejte poglavje 4.4).
Adult patients: Ribavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).
Odrasli bolniki: Zdravilo Ribavirin BioPartners je indicirano v kombinaciji z interferonom alfa-2b za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno odzvali (z normalizacijo vrednosti ALT na koncu zdravljenja) na monoterapijo z interferonom alfa, a se je bolezen kasneje ponovila (glejte poglavje 5.1).
Adult patients: Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed. (see section 5.1).
Odrasli bolniki: Zdravilo Ribavirin Teva je indicirano v kombinaciji z interferonom alfa-2b za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno odzvali (z normalizacijo vrednosti ALT na koncu zdravljenja) na monoterapijo z interferonom alfa, a se je bolezen kasneje ponovila (glejte poglavje 5.1).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1 , not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA (see section 4.4).
Odrasli bolniki: Zdravilo Ribavirin Teva Pharma B.V. je indicirano v kombinaciji s interferonom alfa-2b za zdravljenje odraslih bolnikov z vsemi tipi kroničnega hepatitisa C, razen genotipa 1, ki predhodno še niso bili zdravljeni, nimajo jetrne dekompenzacije, imajo zvišano vrednost alanin-aminotransferaze (ALT) in so pozitivni na ribonukleinsko kislino virusa hepatitisa C RNA-HCV (glejte poglavje 4.4).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA (see section 4.4).
Odrasli bolniki: Zdravilo Ribavirin Teva Pharma B.V. je indicirano v kombinaciji s interferonom alfa-2b za zdravljenje odraslih bolnikov z vsemi tipi kroničnega hepatitisa C, razen genotipa 1, ki predhodno še niso bili zdravljeni, nimajo jetrne dekompenzacije, imajo zvišano vrednost alanin- aminotransferaze (ALT) in so pozitivni na ribonukleinsko kislino virusa hepatitisa C RNA-HCV (glejte poglavje 4.4).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed (see section 5.1).
Odrasli bolniki: Zdravilo Ribavirin Teva Pharma B.V. je indicirano v kombinaciji z interferonom alfa-2b za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno odzvali (z normalizacijo vrednosti ALT na koncu zdravljenja) na monoterapijo z interferonom alfa, a se je bolezen kasneje ponovila (glejte poglavje 5.1).
Adult patients: Ribavirin Teva Pharma B.V. is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.(see section 5.1).
Odrasli bolniki: Zdravilo Ribavirin Teva Pharma B.V. je indicirano v kombinaciji z interferonom alfa-2b za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno odzvali (z normalizacijo vrednosti ALT na koncu zdravljenja) na monoterapijo z interferonom alfa, a se je bolezen kasneje ponovila (glejte poglavje 5.1).
Adult plaque psoriasis
Psoriaza v plakih pri odraslih bolnikih
Adult surgery patients in an autologous predonation programme.
Odrasli kirurški bolniki v programu doniranja avtologne krvi
Adult type 1 and type 2 diabetes titration guideline:
Smernice za titriranje pri odraslih bolnikih s sladkorno boleznijo tipa 1 ali tipa 2
Adult type 2 diabetes simple self titration guideline:
Preproste smernice za samotitriranje pri odraslih bolnikih s sladkorno boleznijo tipa 2
Adult ulcerative colitis
Ulcerozni kolitis pri odraslih bolnikih
adult women (aged 18 years or over) who do not produce eggs and do not respond to treatment with clomiphene citrate (another medicine that stimulates the ovaries to produce eggs); adult women who are undergoing assisted reproductive techniques (fertility treatment) such as in-vitro fertilisation.
pri odraslih ženskah (starejših od 18 let), ki ne proizvajajo jajčec in se ne odzivajo na zdravljenje s klomifen citratom (drugim zdravilom, ki spodbuja jajčnike, da proizvajajo jajčeca); pri odraslih ženskah, ki se zdravijo s postopki asistirane reprodukcije, kot je in vitro oploditev (zdravljenje neplodnosti).
Adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth,
Odraslih žensk, ki so v postopku sprožitve superovulacije pred postopki asistirane reprodukcije, kot je npr. in vitro oploditev (IVF): zdravilo Ovitrelle se uporablja za sprožitev dokončnega folikelskega dozorevanja in luteinizacije po stimulaciji folikelske rasti.